1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Species | Human |
Cat.No | ABC-TC3973 |
Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Product Category | Primary Cells |
Size/Quantity | 1 vial |
Cell Type | DC Cell |
Shipping Info | Dry Ice |
Growth Conditions | 37 ℃, 5% CO2 |
Disease | Normal |
Biosafety Level | 1 |
Storage | Liquid Nitrogen |
Product Type | Nervous Cells |
Human dendritic cells (DCs) are specialized antigen-presenting cells derived from peripheral blood of healthy human donors. These cells are critical in initiating adaptive immune responses by activating naïve T cells and promoting their differentiation into effector cells, while also helping to maintain immune tolerance. In culture, human DCs are non-proliferative and survive for up to 7 days as immature dendritic cells (iDCs) when treated with IL-4 and GM-CSF, and can further differentiate into mature dendritic cells with TNF-α and IL-1β. Morphologically, they exhibit dendritic projections and express a characteristic surface marker profile including CD11c⁺, CD86⁺, CD80⁺, HLA-DR⁺, and CD14⁻, confirmed via flow cytometry. While karyotype analysis is not typically performed, they are widely used in cancer immunotherapy, infectious disease models, and autoimmune disorder research due to their potent antigen-presenting capacity and immunomodulatory role.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Human dendritic cells (DCs) can be used to simulate pathogen-host interactions (such as HIV, SARS-CoV-2) in infectious disease research and evaluate vaccine efficacy through antigen cross-presentation. In addition, in the study of autoimmune diseases, DCs help to elucidate the mechanism of immune tolerance destruction (such as rheumatoid arthritis) and are used to test tolerogenic DC-based therapies to inhibit abnormal immune activation.